Browse the evidence

GLP-1 administration (25 nmol/kg) significantly augments glucose-stimulated insulin secretion and improves glucose tolerance in mice, whereas GLP-2 (25 nmol/kg) improves glucose tolerance without directly augmenting insulin secretion.

Both GLP-1 and GLP-2 peptides improve blood glucose levels in mice, but they do so through different biological pathways. GLP-1 works by telling beta cells to release more insulin, while GLP-2 improves glucose handling without directly increasing insulin secretion. This suggests that targeting GLP-2 receptors could be a viable strategy for glucose control that avoids potential side effects of excessive insulin secretion.

Both GLP-1 and GLP-2 suppress appetite and reduce food intake in mice, regardless of their differential effects on insulin secretion.

Both GLP-1 and GLP-2 peptides reduce food intake in mice, suggesting that GLP-2 could be used to manage appetite without necessarily stimulating insulin secretion. This makes GLP-2 a potential candidate for obesity treatment where insulin secretion is not desired.

Both GLP-1 and GLP-2 promote beta-cell proliferation and protect against cytokine-induced apoptosis, preserving beta-cell mass and function.

Both GLP-1 and GLP-2 help protect beta-cells from death and promote their growth. This suggests that GLP-2 could be used to preserve beta-cell mass in diabetes, potentially slowing disease progression.

Naltrexone/Bupropion is not recommended for individuals with obesity and established atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) due to potential hemodynamic stress and lack of outcome data.

If you have obesity and established heart disease or heart failure, naltrexone/bupropion is not recommended because it can increase heart rate and blood pressure, potentially worsening your condition. Safer, proven alternatives are available.

Semaglutide, despite achieving NASH resolution, failed to improve fibrosis stage in phase 2 trials, highlighting a gap in treating advanced fibrosis compared to resmetirom.

Semaglutide helps resolve NASH but does not improve fibrosis. Patients with advanced fibrosis should consider other options like resmetirom.

Obeticholic acid (OCA) trials for NASH were discontinued due to safety concerns and modest efficacy, despite showing some histological improvement.

Obeticholic acid is not approved for NASH due to safety issues.

Lixisenatide and high-dose efpeglenatide (6 mg/week) are associated with a statistically significant increase in hearing loss events compared to controls, whereas other GLP-1 receptor agonists and SGLT2 inhibitors do not demonstrate this elevated risk.

If you are taking Lixisenatide or high-dose Efpeglenatide, be aware of a potential increased risk of hearing loss. This risk is not seen with other GLP-1 drugs like Semaglutide or Dulaglutide in this analysis. Report any sudden hearing changes to your doctor immediately, but do not stop your medication without consulting them, as the absolute risk (NHH ~757) is relatively low.

Current randomized controlled trials of nutrient-stimulated hormone-based therapies (NuSHs) for obesity predominantly fail to assess nutritional and functional outcomes, focusing almost exclusively on body weight.

If you are participating in or designing a NuSH trial, you must include nutritional and functional assessments (body composition, muscle strength, bone health) alongside weight. Relying solely on weight masks potential risks like sarcopenia and bone loss.

Current NuSH trials rarely assess bone health, despite the known risk of bone mass reduction associated with significant weight loss.

If you are on NuSHs, ask your doctor about bone density scans, especially if you are post-menopausal or elderly. Ensure adequate calcium and vitamin D intake, as weight loss can compromise bone strength.

Obesity (BMI ≥30 kg/m2) significantly increases annual health care resource utilization (HCRU) and causes substantial premature mortality, resulting in billions of pounds in lifetime economic loss and quality-adjusted life year (QALY) deficits.

Obesity imposes a massive financial and health burden on society, costing billions in healthcare resources and causing significant premature death. While losing weight reduces annual healthcare costs, the benefit is largely negated by the increased life expectancy of formerly obese individuals, meaning the total lifetime cost remains high. Public health policy must account for this lifetime cost, not just short-term annual savings.

Socioeconomic deprivation is strongly correlated with higher prevalence of obesity (BMI ≥40) and higher mortality rates, with the most deprived areas facing the greatest healthcare burden.

Obesity and its associated health risks are significantly higher in socioeconomically deprived areas. Public health interventions should target these areas, as they bear the greatest burden of obesity-related mortality and healthcare costs.

Biological mechanisms, specifically a defended weight set point driven by genetic and epigenetic factors, actively oppose weight loss maintenance by altering hunger hormones and reducing energy expenditure, making long-term weight loss difficult without continuous intervention.

Accept that maintaining weight loss is biologically harder than losing it due to hormonal defenses. Do not rely on short-term diets; instead, focus on long-term strategies like preventing 'weight creep' (0.5-1kg/year gain) through low-intensity lifestyle changes or considering long-term pharmacological support (like GLP-1 agonists or metformin) if indicated, rather than expecting a one-time fix.

Protein restriction (specifically low-protein, high-carbohydrate diets) extends lifespan and improves metabolic health in model organisms, likely through mechanisms distinct from or overlapping with calorie restriction, such as elevated FGF21.

In model organisms, restricting protein (while keeping calories normal) extends lifespan and improves metabolic health, partly by boosting FGF21. However, this comes at the cost of muscle mass. For humans, high protein is generally recommended for muscle maintenance, but excessive intake might increase mortality risk. The optimal protein intake likely balances longevity benefits with the need to preserve physical resilience, suggesting a moderate approach rather than extreme restriction or excess.

Chronic chicken meat intake and resistance training do not drastically alter gut microbiota composition in elderly women, contradicting hypotheses that such interventions significantly shift microbial diversity.

You do not need to worry about chicken meat or resistance training negatively impacting or drastically altering your gut microbiota in a harmful way. The study found no significant changes in gut bacteria diversity, suggesting these interventions are safe for gut health in this demographic.

Individuals with greater personal success in weight loss without medication exhibit higher obesity stigma and less favorable attitudes toward anti-obesity medications.

Healthcare providers should recognize that patients who have successfully lost weight through diet and exercise may be skeptical of or stigmatizing toward GLP-1 medications. Counseling should validate their success while explaining that biological factors can persist despite lifestyle efforts, making medication a valid and effective tool for others.

Male sex, older age (≥65 years), lower socioeconomic status (lower income, less education, higher area deprivation), and lack of insurance are associated with significantly lower odds of receiving anti-obesity medication (AOM) prescriptions and metabolic and bariatric surgery (MBS).

If you are male, older, or have limited income/insurance, you face significant systemic barriers to accessing obesity treatments like GLP-1s or surgery. This is not a reflection of your medical need but of socio-economic disparities. Seek providers who are aware of these disparities and advocate for coverage options or financial assistance programs.

Activation of Glucagon-Like Peptide-1 Receptors (GLP-1R) in the Gustatory Cortex (GC) reduces homeostatic food intake in mice.

This research identifies a specific brain region (Gustatory Cortex) where GLP-1 receptors are active and influence how much we eat. While this doesn't change current dietary advice, it explains part of the mechanism behind GLP-1 based weight loss drugs, suggesting they work by altering how the brain processes taste and hunger signals, not just by signaling fullness from the gut.

The effect of GC GLP-1R activation on food intake is conditional on the palatability and fat content of the food, particularly in mice chronically maintained on a high-fat diet.

If you are trying to lose weight, switching from a high-fat diet to a lower-fat diet might make appetite-suppressing medications (like GLP-1 agonists) more effective. The brain's response to these drugs seems to depend on the palatability of the food, and changing your diet may help reset these signals.

GIPR agonism in humans may not provide weight loss benefits and can negate the appetite-suppressing effects of GLP-1.

While GIPR agonists work in animals, human studies show that adding GIP to GLP-1 can actually stop GLP-1 from working as well for appetite control. This suggests the human body responds differently than mice.

DPP-4 inhibitors (specifically Saxagliptin and Alogliptin) may increase the risk of hospitalization for heart failure, whereas Sitagliptin and Linagliptin appear neutral.

If you have Type 2 Diabetes and Heart Failure, be cautious with DPP-4 inhibitors. Saxagliptin and Alogliptin have been linked to an increased risk of heart failure hospitalization. However, Sitagliptin and Linagliptin have shown neutral effects. Discuss the specific risks and benefits with your doctor to choose the safest option for your heart.

GLP1R-expressing neurons in the human hypothalamus, specifically those co-expressing POMC in the arcuate nucleus and AVP in the paraventricular/supraoptic nuclei, are the primary neural targets mediating the appetite-suppressing effects of GLP-1 receptor agonists like semaglutide.

If you are using a GLP-1 medication like semaglutide, its ability to reduce your appetite is biologically grounded in its action on specific neurons in your hypothalamus (brain). This confirms that the reduction in food intake is a direct neurological effect, not just a side effect of slower digestion.

GIPR (Gastric Inhibitory Polypeptide Receptor) is expressed in human hypothalamic ependymal cells surrounding the third ventricle, suggesting a potential mechanism for how GIPR-targeting drugs like tirzepatide access the brain.

This research suggests that drugs targeting the GIP receptor (like tirzepatide) may interact with cells lining the fluid spaces in your brain. This provides a biological basis for how these medications might influence brain function related to appetite, beyond just their effects on the stomach.

Rare deleterious variants in the gene CORO1A are significantly associated with changes in BMI at the population level, identifying it as a novel genetic factor in obesity risk.

Genetic testing may reveal variants in the CORO1A gene that predispose individuals to higher BMI. This is a newly identified genetic risk factor.

Second-generation oral contraceptive pill phase (active vs. inactive) does not influence muscle protein synthesis or myofibrillar proteolysis at rest or in response to resistance exercise.

If you take second-generation birth control pills, you can train for muscle growth without worrying about your pill cycle. Your muscles build and break down protein at the same rate whether you are on the active pills or the placebo week. Focus on your training and nutrition; the pill phase does not matter for your results.